Minoryx raises €51 million to support Marketing Authorization Application and launch preparations for X-linked Adrenoleukodystrophy (X-ALD) therapy Funds will support the marketing authorization review process for male ... 31/05/2022
Additional data from Minoryx’s Phase 2/3 ADVANCE clinical trial presented at American Neurological Association (ANA) 2021 Presentation highlights reduction in cerebral lesion progression and the risk ... 03/11/2021
Minoryx publishes mechanism of action of leriglitazone in X-ALD in Science Translational Medicine journal Published data highlights therapeutic potential for all forms of X-ALD ... 03/06/2021
15 Mar 2022 - 20 Mar 2022 AD/PD2022 International Conference on Alzheimer's and Parkinson's Diseases VIRTUAL
17 Oct 2021 - 19 Oct 2021 ANA 2021 - 16th Annual Meeting of the American Neurological Association VIRTUAL
Headquarters https://www.minoryx.com/content/imgs/mail/logo.png Av. Ernest Lluch 32 - TCM3 08302 Mataró (Barcelona) Spain
Belgian R&D Site https://www.minoryx.com/content/imgs/mail/logo.png Rue Auguste Piccard 48, I - Tech Incubator 6041 Gosselies (Charleroi) Belgium